Effect of Anatabine on Elevated Blood Levels of C-reactive Protein

Sponsor
Roskamp Institute Inc. (Other)
Overall Status
Completed
CT.gov ID
NCT01607619
Collaborator
(none)
117
3
20.1
39
1.9

Study Details

Study Description

Brief Summary

The investigators are studying a dietary supplement called anatabine in a lozenge form named RCP006. The main purpose of this study is to evaluate the effects of this dietary supplement on normal human inflammatory function. The investigators will see this effect in volunteers who have markers of higher levels of inflammation to begin with. The investigators anticipate that anatabine will reduce markers of inflammation. Therefore the investigators are looking for volunteers with high blood levels of C-reactive Protein (CRP) and will monitor the blood CRP levels at several time points throughout the study.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Anatabine
N/A

Detailed Description

The investigators are studying a dietary supplement called anatabine which for the purposes of this study has been made into lozenges and named RCP006. Anatabine, the only active ingredient of RCP006, occurs throughout the world in the human food chain. Anatabine has been in the human food supply and in human use for centuries. Humans are exposed to anatabine in tobacco products and common and widely consumed food crops such as potatoes, peppers, eggplants and tomatoes. The main purpose of this study is to evaluate the effects of this dietary supplement on normal human inflammatory function. Compounds that are chemically similar to anatabine have been shown to reduce inflammatory responses, and laboratory studies show anti-inflammatory properties for anatabine. The investigators want to explore this further in human studies to see if anatabine can maintain normal levels of inflammatory function. The investigators will see this effect more easily if the investigators look at the effects of anatabine in volunteers who have markers of higher levels of inflammation to begin with. The investigators anticipate that anatabine will reduce markers of inflammation. To look for inflammation the investigators will test blood levels of a protein called C-reactive protein. C-reactive protein (CRP) is a protein found in the blood, the levels of which rise in response to inflammation. Therefore the investigators are looking for volunteers with high blood levels of CRP and will monitor the blood CRP levels at several timepoints throughout the study. The investigators will also collect blood samples to measure other indicators of inflammation, and to measure blood levels of anatabine.

Study Design

Study Type:
Interventional
Actual Enrollment :
117 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
A 12-week Multi-site Trial of the Dietary Supplement Anatabine (RCP006) to Determine the Effects on Peripheral Markers of Inflammation in Patients With Elevated Levels of C-reactive Protein (CRP)
Study Start Date :
May 1, 2011
Actual Primary Completion Date :
Jan 1, 2013
Actual Study Completion Date :
Jan 1, 2013

Outcome Measures

Primary Outcome Measures

  1. Blood levels of hsCRP [Days 1, 14, 42, 70]

Secondary Outcome Measures

  1. Blood levels of inflammatory markers [Days 1, 14, 42, 70]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • healthy adults with elevated blood levels of hsCRP
Exclusion Criteria:
  • pregnancy or planning pregnancy

  • current tobacco use

  • current steroid use

  • allergy to study product components

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Roskamp Institute, Inc. Sarasota Florida United States 34243
2 McLaren Community Medical Center Flint Michigan United States 48532
3 Medical Practice Shelby Township Michigan United States 48315

Sponsors and Collaborators

  • Roskamp Institute Inc.

Investigators

  • Principal Investigator: Dale Wilson, MD, McLaren Community Medical Center
  • Principal Investigator: Vittorio Morreale, MD, Medical Practice, Shelby Township

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Roskamp Institute Inc.
ClinicalTrials.gov Identifier:
NCT01607619
Other Study ID Numbers:
  • RI-11-01
First Posted:
May 30, 2012
Last Update Posted:
Jan 28, 2013
Last Verified:
Jan 1, 2013
Keywords provided by Roskamp Institute Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 28, 2013